Objectives: Tirzepatide and chromium picolinate have been found in Type 2 Diabetes Mellitus patients to improve glycemic management by slowing weight gain and improving lipid profiles. The aim of this paper is a mini comparative investigation of these two drugs in Type 2 Diabetes for their effectiveness in weight control and weight loss. This paper will scientifically assess the effects of tirzepatide and dietary adjuvant therapy on a range of metabolic health markers through a thorough assessment of clinical data. The results of this study will help to make educated and practical treatment choices for the condition. The data was abstracted from various databases available such as PubMed, Science Direct, and Google Scholar, utilizing keywords such as tirzepatide, chromium picolinate, glycemic control, and weight loss. The effect of Tirzepatide and Chromium picolinate for glycemic control and weight control was studied. Additionally, their common interactions and side effects were listed, various clinical trial study data on both drugs was summarized and interpretations were made accordingly.
Bisht* et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: